Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
2020 · British Journal of Cancer · 41 citations
https://doi.org/10.1038/s41416-020-0833-7
E
Elisabetta Zulato
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
89
Papers
1.4K
Citations
18
h-index
27
i10-index
Elisabetta Zulato is an academic researcher from Istituto Oncologico Veneto. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer, Hypoxia, and Metabolism & Cancer Genomics and Diagnostics. The author has an h-index of 18, co-authored 76 publications.
ORCID: 0000-0002-2624-5060Papers by this author
worksBinary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC
2024 · Scientific Reports · 2 citations
https://doi.org/10.1038/s41598-024-68229-6
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy
2019 · Annals of Oncology · 0 citations
https://doi.org/10.1093/annonc/mdz073.005
104P The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.08.112
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat